Does Impella reduce major adverse kidney events in patients undergoing elective high-risk PCI compared to intra-aortic balloon pump support?
4,666 propensity score-matched patients (from an initial 7,872) undergoing elective high-risk PCI with Impella or IABP support between 2017 and 2025 from the US TRUVETA database.
Impella support during elective high-risk PCI
Intra-aortic balloon pump (IABP) support during elective high-risk PCI
Major adverse kidney events (MAKE, composite of all cause mortality, renal replacement therapy, and acute kidney injury) at 90 dayscomposite
In patients undergoing elective high-risk PCI, Impella support was associated with a lower 90-day risk of major adverse kidney events compared to IABP support.
Conclusions: We have shown that there is a gap in CTO-PCI procedural success rates between high volume and low volume operators.
Building similarity graph...
Analyzing shared references across papers
Loading...
Zweck et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69edab424a46254e215b367f — DOI: https://doi.org/10.1016/j.jscai.2026.105039
E Zweck
Ralf Westenfeld
Andrew Shaw
Journal of the Society for Cardiovascular Angiography & Interventions
Düsseldorf University Hospital
Hochschule Düsseldorf University of Applied Sciences
Life Science Center Düsseldorf (Germany)
Building similarity graph...
Analyzing shared references across papers
Loading...